Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

IL-10-Induced miR-155 Targets SOCS1 To Enhance IgE-Mediated Mast Cell Function.

Qayum AA, Paranjape A, Abebayehu D, Kolawole EM, Haque TT, McLeod JJ, Spence AJ, Caslin HL, Taruselli MT, Chumanevich AP, Baker B, Oskeritzian CA, Ryan JJ.

J Immunol. 2016 Jun 1;196(11):4457-67. doi: 10.4049/jimmunol.1502240. Epub 2016 Apr 29.

PMID:
27183599
2.

IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3.

Desai A, Jung MY, Olivera A, Gilfillan AM, Prussin C, Kirshenbaum AS, Beaven MA, Metcalfe DD.

J Allergy Clin Immunol. 2016 Jun;137(6):1863-1871.e6. doi: 10.1016/j.jaci.2015.09.059. Epub 2016 Jan 7.

PMID:
26774658
3.

Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33.

Bandara G, Beaven MA, Olivera A, Gilfillan AM, Metcalfe DD.

Eur J Immunol. 2015 Nov;45(11):3034-44. doi: 10.1002/eji.201545501. Epub 2015 Sep 9.

PMID:
26256265
4.

The adaptor 3BP2 is required for KIT receptor expression and human mast cell survival.

Ainsua-Enrich E, Serrano-Candelas E, Álvarez-Errico D, Picado C, Sayós J, Rivera J, Martín M.

J Immunol. 2015 May 1;194(9):4309-18. doi: 10.4049/jimmunol.1402887. Epub 2015 Mar 25.

5.

Modulation of mast cell proliferative and inflammatory responses by leukotriene d4 and stem cell factor signaling interactions.

Al-Azzam N, Kondeti V, Duah E, Gombedza F, Thodeti CK, Paruchuri S.

J Cell Physiol. 2015 Mar;230(3):595-602. doi: 10.1002/jcp.24777.

6.

Mast cell function: a new vision of an old cell.

da Silva EZ, Jamur MC, Oliver C.

J Histochem Cytochem. 2014 Oct;62(10):698-738. doi: 10.1369/0022155414545334. Epub 2014 Jul 25. Review.

7.

Establishment of a mast cell line, NCL-2, without Kit mutation, derived from NC mouse bone marrow.

Hiragun T, Yanase Y, Okabe T, Hiragun M, Kawai M, Hide M.

FEBS Open Bio. 2014 Apr 2;4:342-6. doi: 10.1016/j.fob.2014.03.011. eCollection 2014.

8.

Mast cell plasticity and sphingosine-1-phosphate in immunity, inflammation and cancer.

Oskeritzian CA.

Mol Immunol. 2015 Jan;63(1):104-12. doi: 10.1016/j.molimm.2014.03.018. Epub 2014 Apr 22. Review.

9.

Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.

Chan EC, Bai Y, Kirshenbaum AS, Fischer ER, Simakova O, Bandara G, Scott LM, Wisch LB, Cantave D, Carter MC, Lewis JC, Noel P, Maric I, Gilfillan AM, Metcalfe DD, Wilson TM.

J Allergy Clin Immunol. 2014 Jul;134(1):178-87. doi: 10.1016/j.jaci.2013.12.1090. Epub 2014 Feb 28.

10.

Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress.

Huang L, Wong CC, Mackenzie GG, Sun Y, Cheng KW, Vrankova K, Alston N, Ouyang N, Rigas B.

BMC Cancer. 2014 Feb 28;14:141. doi: 10.1186/1471-2407-14-141.

11.

Mast cell activity in the healing wound: more than meets the eye?

Wulff BC, Wilgus TA.

Exp Dermatol. 2013 Aug;22(8):507-10. doi: 10.1111/exd.12169. Epub 2013 Jun 27. Review.

12.

A truncated splice-variant of the FcεRIβ receptor subunit is critical for microtubule formation and degranulation in mast cells.

Cruse G, Beaven MA, Ashmole I, Bradding P, Gilfillan AM, Metcalfe DD.

Immunity. 2013 May 23;38(5):906-17. doi: 10.1016/j.immuni.2013.04.007. Epub 2013 May 2.

13.

Prevention of F-actin assembly switches the response to SCF from chemotaxis to degranulation in human mast cells.

Smrž D, Bandara G, Beaven MA, Metcalfe DD, Gilfillan AM.

Eur J Immunol. 2013 Jul;43(7):1873-82. doi: 10.1002/eji.201243214. Epub 2013 Jun 4.

14.

Knockout of the Trpc1 gene reveals that TRPC1 can promote recovery from anaphylaxis by negatively regulating mast cell TNF-α production.

Medic N, Desai A, Olivera A, Abramowitz J, Birnbaumer L, Beaven MA, Gilfillan AM, Metcalfe DD.

Cell Calcium. 2013 May-Jun;53(5-6):315-26. doi: 10.1016/j.ceca.2013.02.001. Epub 2013 Mar 13.

15.

A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses.

Smrž D, Bandara G, Zhang S, Mock BA, Beaven MA, Metcalfe DD, Gilfillan AM.

J Immunol Methods. 2013 Apr 30;390(1-2):52-62. doi: 10.1016/j.jim.2013.01.008. Epub 2013 Jan 25.

16.

IL-33 induces a hyporesponsive phenotype in human and mouse mast cells.

Jung MY, Smrž D, Desai A, Bandara G, Ito T, Iwaki S, Kang JH, Andrade MV, Hilderbrand SC, Brown JM, Beaven MA, Metcalfe DD, Gilfillan AM.

J Immunol. 2013 Jan 15;190(2):531-8. doi: 10.4049/jimmunol.1201576. Epub 2012 Dec 17.

17.

The essential adaptors of innate immune signaling.

Chen H, Jiang Z.

Protein Cell. 2013 Jan;4(1):27-39. doi: 10.1007/s13238-012-2063-0. Epub 2012 Sep 21. Review.

18.

Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation.

Bai Y, Bandara G, Ching Chan E, Maric I, Simakova O, Bandara SN, Lu WP, Wise SC, Flynn DL, Metcalfe DD, Gilfillan AM, Wilson TM.

Leukemia. 2013 Feb;27(2):278-85. doi: 10.1038/leu.2012.218. Epub 2012 Jul 31. Review.

19.

Shp2 activates Fyn and Ras to regulate RBL-2H3 mast cell activation following FcεRI aggregation.

Fang X, Lang Y, Wang Y, Mo W, Wei H, Xie J, Yu M.

PLoS One. 2012;7(7):e40566. doi: 10.1371/journal.pone.0040566. Epub 2012 Jul 10.

20.

Mast cell adenosine receptors function: a focus on the a3 adenosine receptor and inflammation.

Rudich N, Ravid K, Sagi-Eisenberg R.

Front Immunol. 2012 Jun 4;3:134. doi: 10.3389/fimmu.2012.00134. eCollection 2012.

Items per page

Supplemental Content

Write to the Help Desk